---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Humanistic burden and health-related quality of life. Topics: Health-related quality of life and SF-6D utility in apparent treatment-resistant hypertension on four or more drug classes: MEPS 2000 to 2011, Proposed contributors to lower quality of life in treatment-resistant hypertension: review, SF-36 and SF-12 scores in hypertension compared with normotension: meta-analysis of 20 studies, EQ-5D index scores for hypertension and its cardiovascular complications: US catalogue from MEPS 2000 to 2002, and 7 further topics. 11 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### Health-related quality of life and SF-6D utility in apparent treatment-resistant hypertension on four or more drug classes: MEPS 2000 to 2011

> “We aimed to compare HrQoL measures in adults with apparent TRH (aTRH) and non-resistant hypertension among nationally representative US Medical Expenditure Panel Survey data pooled from 2000 to 2011.”
> “2501 (4.4%) met criteria for aTRH.”
> “Persons with aTRH, compared with non-resistant hypertension, had lower mean PCS scores (35.8 vs 43.2; P<0.0001), and utility (0.68 vs 0.74; P<0.0001), but similar MCS scores (49.1 vs 50.4).”
> “In multivariable-adjusted analyses, aTRH was associated with a 2.37 (95% CI 1.71 to 3.02) lower PCS score and 0.02 (95% CI 0.01 to 0.03) lower utility, compared with non-resistant hypertension.”
> “In conclusion, aTRH was associated with substantially lower HrQoL in physical functioning and health utility, but not in mental functioning, compared with non-resistant hypertension.”

Source: [Carris et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26084656/)

<a id="topic-2.2.1.8.1-2"></a>

### Proposed contributors to lower quality of life in treatment-resistant hypertension: review

> “Recent evidence, although limited, suggests that TRH may also adversely affect health-related quality of life (HrQoL) and other patient-reported outcomes.”
> “A number of recent studies focusing on both the general hypertensive population and those with TRH suggest that patient awareness of difficult-to-control blood pressure, chronically elevated blood pressure levels, and the use of aggressive medication regimens with attendant cumulative adverse effects may play significant roles.”

Source: [Carris and Smith (2015)](https://pubmed.ncbi.nlm.nih.gov/26115629/)

<a id="topic-2.2.1.8.1-3"></a>

### SF-36 and SF-12 scores in hypertension compared with normotension: meta-analysis of 20 studies

> “Most of the 20 studies selected for the systematic review identified lower quality of life in patients with hypertension, but they were very heterogeneous in regard to selection criteria and comparison groups, limiting their external validity.”
> “The meta-analysis identified lower scores in hypertensive patients for physical [-2.43; 95% confidence interval (CI) -4.77 to -0.08] and mental (-1.68; 95% CI -2.14 to -1.23) components.”
> “Quality of life of individuals with hypertension is slightly worse than that of normotensive individuals.”

Source: [Trevisol et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21045726/)

<a id="topic-2.2.1.8.1-4"></a>

### EQ-5D index scores for hypertension and its cardiovascular complications: US catalogue from MEPS 2000 to 2002

> “The nationally representative Medical Expenditure Panel Survey (MEPS) was pooled (2000−2002) to create a data set of 38,678 adults.”

Source: [Sullivan and Ghushchyan (2006)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2634296/)

| ICD-9 condition | Respondents (n) | Unadjusted mean EQ-5D | Median EQ-5D | Adjusted disutility (CLAD regression) |
| --- | --- | --- | --- | --- |
| 401 Essential hypertension | “7085” | “0.789” | “0.816” | “−0.0250” |
| 410 Acute myocardial infarction | “244” | “0.704” | “0.778” | “−0.0409” |
| 414 Other chronic ischemic heart disease | “183” | “0.738” | “0.794” | “−0.0336” |
| 428 Heart failure | “284” | “0.636” | “0.708” | “−0.0635” |
| 436 Cerebrovascular accident | “340” | “0.650” | “0.768” | “−0.0524” |

Source: [Sullivan and Ghushchyan (2006)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2634296/)

<a id="topic-2.2.1.8.1-5"></a>

### Health state utilities used in the ICER model of aldosterone synthase inhibitors

> “Patients in the hypertension alone state were assigned an age-specific background utility for the US general population, consistent with prior models”
> “For patients occupying more than one event state, a multiplicative approach was used to combine the relevant condition-specific utilities, consistent with standard practice in multi-state cost-effectiveness models.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Health state | Utility or disutility |
| --- | --- |
| Hypertension alone | “Age-specific” |
| Acute myocardial infarction, disutility (3 months) | “-0.15” |
| Post-myocardial infarction, disutility | “-0.041” |
| Acute stroke, disutility (3 months) | “-0.19” |
| Post-stroke, disutility | “-0.052” |
| Coronary heart disease, disutility | “-0.034” |
| Heart failure, disutility | “-0.064” |
| End-stage kidney disease, disutility | “-0.170” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.1.8.1-6"></a>

### EQ-5D-5L quality of life in 56 participants with resistant hypertension: RHYME-RCT

> “A total of 56 patients with median age 61.5 [25th–75th percentile: 55.8–69.3] years (21.4% women) were included.”
> “At 12 months, no differences were observed in EQ-5D-5L index (0.81 [0.69–0.89] vs. 0.89 [0.73–1.00]; P = 0.18) and visual analogue scale score on general patient-perceived health (70 [60–80] vs. 70 [60–82]; P = 0.53) between the intervention-arm and the standard-of-care only-arm.”
> “Irrespective of the intervention, independent positive predictors of the percentage adherence were patient age, EQ-5D-5L index score, BMQ-specific necessity score and concern score, whereas the total number of drugs prescribed was a negative predictor.”

Source: [Zeijen et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11356742/)

<a id="topic-2.2.1.8.1-7"></a>

### Treatment burden: patient input on pill burden, copays, and coverage barriers

> “For example, many people living with hypertension report needing to take multiple medications.”
> “While almost all antihypertensive medications have an available generic alternative and cost for individual drugs is rarely a barrier to adherence, pill burden, additive copays for multiple medications, variable tolerance for side effects such as frequent urination with diuretics or edema with calcium channel blockers, and a lack of awareness of the importance of treating hypertension – particularly in people without symptoms – can decrease adherence and persistence to treatment.”
> “We heard that insurance coverage barriers, such as prior authorization and step therapy, can place a high burden on patients and can cause people to abandon treatment.”
> “People living with hypertension expressed hope that new medications would be more effective than older medications, allowing them to decrease the number of medications they need to take to control their blood pressure.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.1.8.1-8"></a>

### Pill burden and nonadherence in resistant hypertension: review

> “Reasons include adverse drug effects, pill burden, drug costs, long duration of treatment, and lack of communication from clinicians about the importance of medication adherence and persistence”
> “Because adherence declines as the number of medications rises and the treatment regimen becomes more complex, poor adherence is a particular problem complicating the treatment of patients with RHT”

Source: [Flack et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11533979/)

<a id="topic-2.2.1.8.1-9"></a>

### Number of prescribed antihypertensive drugs and biochemically confirmed nonadherence in 1348 participants

> “We used high-performance liquid chromatography-tandem mass spectrometry of urine and serum to detect nonadherence and explored its association with the main demographic- and therapy-related factors in 1348 patients with hypertension from 2 European countries.”
> “The rates of nonadherence to antihypertensive treatment were 41.6% and 31.5% in the UK and Czech populations, respectively.”
> “Each increase in the number of antihypertensive medications led to 85% and 77% increase in nonadherence (P<0.001) in the UK and Czech populations, respectively.”
> “We demonstrate that the number and class of prescribed antihypertensives are modifiable risk factors for biochemically confirmed nonadherence to blood pressure-lowering therapy.”

Source: [Gupta et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28461599/)

<a id="topic-2.2.1.8.1-10"></a>

### Prevalence of medication nonadherence in apparent treatment-resistant hypertension: meta-analysis of 24 studies

> “From an initial discovery of 921 studies, we identified 24 studies that measured medication adherence for patients with uncontrolled BP despite being prescribed three or more antihypertensive medications of different classes.”
> “By using a random effects model, the pooled prevalence of nonadherence was 31.2% (95% confidence interval = 20.2-44.7, I = 99.50) with nonadherence rates ranging from 3.3 to 86.1%.”
> “Findings indicate that medication nonadherence is a significant problem among aTRH patients.”

Source: [Durand et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28777133/)

<a id="topic-2.2.1.8.1-11"></a>

### Regimen simplification: single-pill compared with free-equivalent combination therapy, systematic review of 44 studies

> “Following screening, 44 studies were included. The majority (18 of 23) of studies measuring adherence showed adherence was significantly improved in patients receiving SPCs versus FECs.”
> “SPC therapy leads to improved adherence and persistence compared with FEC therapy and may lead to better BP control in patients with hypertension.”

Source: [Parati et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33390044/)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
